Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.